Pharmaceutical

Coherus acquires immuno-oncology company Surface

Coherus BioSciences has concluded the acquisition of immuno-oncology (I-O) company Surface Oncology in a deal totalling nearly $66.9m.

Sep 11, 2023 - 20:00
Coherus acquires immuno-oncology company Surface
Coherus BioSciences has concluded the acquisition of immuno-oncology (I-O) company Surface Oncology in a deal totalling nearly $66.9m.
Read the original article

Tags:

Previous Article

Signal: Kroger to pay up to $1.4bn to settle opioid crisis lawsuits

Next Article

Grit Biotechnology secures funds for development of pipeline programmes

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: European regulators once again recommend Amylyx’s ALS drug be rejected

STAT+: European regulators once again recommend Amylyx’...

Oct 14, 2023

SOR-007 by Nanology for Metastatic Adenocarcinoma of Th...

Dec 22, 2023

Exploring Melbourne’s booming life sciences sector

Exploring Melbourne’s booming life sciences sector

Jul 16, 2024